B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

Benzinga · 2d ago
B. Riley Securities analyst Madison El-Saadi assumes Anika Therapeutics (NASDAQ:ANIK) with a Buy rating and raises Price Target to $23.